Stamford, CT -- (SBWIRE) -- 02/22/2013 -- Jet Life Penny Stocks provides investors with the Best penny stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletters and offer you the tools to help you along the way with the goal of keeping you loyal to our service.
Advaxis, Inc. (OTC:ADXS) It opened the session at $0.12 and remained in $0.11 and $0.12 price range during the session. The stock is 18.81 percent higher at $0.120. Volume closed the day at 6.96 million shares, its average volume being 6.86 million shares.
The company has total of 392.28 million outstanding shares and its total market capitalization is $47.07million. Its beta value stands at 1.85 times and earnings per share was $-0.05.
Should ADXS a Buy or Sell Now? Find Out Here
ADXS was a gainer in the 5 days activity and jumped about 30.43%. The one month performance of stock was positive and it scored more than 71.43%.Advaxis, Inc., (OTC: ADXS) reported that the Brown University Oncology Research Group (BrUOG) will be coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer. Dr. Howard Safran, professor of medicine, will be principal investigator. Patients will be treated at Rhode Island Hospital and The Miriam Hospital (the main teaching hospitals of The Warren Alpert Medical School of Brown University). Multiple institutions will collaborate.
Advaxis, Inc., (ADXS) is a leader in developing the next generation of immunotherapies for cancer and infectious diseases.
MultiCell Technologies, Inc. (PINK:MCET) traded in the range of $0.0032 and $0.0045 in its previous trading session. The stock recorded the volume of 86.04 million shares so far, in comparison its average daily trading volume of 30.96 million shares. The company has total of 1.24 billion outstanding shares and its total market capitalization is $4.10 million.
Can MCET Show a Strong Recovery? Find out in This Research Report
Company’s year to date performance remained quiet optimistic with the rise of 175%. If we look at last 6 months of trade that is in bullish zone with an increase of 120%
The stock opened at $0.0043 and its closing price for the day was $0.0033, down -23.26 percent. The beta of the MCET stands at -1.18. 52 week range of the stock is $0.001-$0.0064.MultiCell Technologies, Inc., is a biopharmaceutical company, engages in the research, development, and commercialization of therapeutic products by using its immune system modulation technologies. The company focuses on the research and development of therapeutics that targeting degenerative neurological diseases, including multiple sclerosis and cancer.
TRANZBYTE CORPORATIO (PINK:ERBB) experienced a plunge of -15.66%. After opening the day at $0.01 per share, volume surged to 75.85 million, leaving behind its daily average volume of 81.68million shares. Beta value for the Company stands at 2.20, indicating its risk level. The stock remained in $0.01 and $0.01 price range during the session.
Where ERBB is Headed Exactly? Find out in This Trend Analysis Reports
Company’s graphical value indicates these stories about the stocks: During last 5 trades the stock plummeted almost -53.02%. During last one month it rose with the percentage of 66.67. Its year to date performance remained progressive with 180%.
Stock touched its 52 week highest price point at $0.02.Tranzbyte Corporation, through its subsidiaries, operates independently owned retail dispensaries under the Altitude Organic Medicine brand name in Colorado, California, and Arizona. It also offers specialized business support services; and sells horticulture equipment.
About Jetlifepennystock.com
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Jet Life Penny Stocks also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Disclaimer
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)